In vitro immunization of human lymphocytes with human lung cancer cell line A549

Hiroharu Kawahara, Sanetaka Shirahata, Hirofumi Tachibana, Hiroki Murakami

研究成果: ジャーナルへの寄稿記事

24 引用 (Scopus)

抄録

We established a method of in vitro immunization of human lymphocytes against human cancer cells and efficiently obtained human-human hybridomas producing cancer-specific antibodies using the in vitro immunized lymphocytes. Human lymphocytes were cocultured with human lung cancer cell line A549 for four days in medium containing various immunoactive reagents. In vitro immunization was effectively caused by the addition of OK-432 or muramyl peptides, IL-2, and IL-6, to the coculture of A549 cells and lymphocytes. Although specific antibodies of both IgM and IgG classes were produced by this method, the ratio of IgG to IgM was ≥2. The efficiencies of in vitro immunization fluctuated about threefold in lymphocytes derived from several donors. The in vitro immunized lymphocytes were fused with human fusion partner A4H12 cells. Hybridomas producing specific antibodies reactive to A549 cells were efficiently obtained by sequential cell fusion. The efficiency of acquisition of hybridom as producing specific antibodies with the in vitro immunized lymphocytes was about 10-fold higher than that with lymphocytes spontaneously immunized in bodies of lung cancer patients.

元の言語英語
ページ(範囲)8-13
ページ数6
ジャーナルHuman Antibodies
3
発行部数1
DOI
出版物ステータス出版済み - 1 1 1992

Fingerprint

Immunization
Lung Neoplasms
Lymphocytes
Antibodies
Hybridomas
Immunoglobulin M
Immunoglobulin G
Picibanil
A549 Cells
In Vitro Techniques
Cell Fusion
Coculture Techniques
Interleukin-2
Interleukin-6
Neoplasms
Tissue Donors
Peptides

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

これを引用

In vitro immunization of human lymphocytes with human lung cancer cell line A549. / Kawahara, Hiroharu; Shirahata, Sanetaka; Tachibana, Hirofumi; Murakami, Hiroki.

:: Human Antibodies, 巻 3, 番号 1, 01.01.1992, p. 8-13.

研究成果: ジャーナルへの寄稿記事

Kawahara, Hiroharu ; Shirahata, Sanetaka ; Tachibana, Hirofumi ; Murakami, Hiroki. / In vitro immunization of human lymphocytes with human lung cancer cell line A549. :: Human Antibodies. 1992 ; 巻 3, 番号 1. pp. 8-13.
@article{4dc90630ac994a07b8099aab1d3d3cf9,
title = "In vitro immunization of human lymphocytes with human lung cancer cell line A549",
abstract = "We established a method of in vitro immunization of human lymphocytes against human cancer cells and efficiently obtained human-human hybridomas producing cancer-specific antibodies using the in vitro immunized lymphocytes. Human lymphocytes were cocultured with human lung cancer cell line A549 for four days in medium containing various immunoactive reagents. In vitro immunization was effectively caused by the addition of OK-432 or muramyl peptides, IL-2, and IL-6, to the coculture of A549 cells and lymphocytes. Although specific antibodies of both IgM and IgG classes were produced by this method, the ratio of IgG to IgM was ≥2. The efficiencies of in vitro immunization fluctuated about threefold in lymphocytes derived from several donors. The in vitro immunized lymphocytes were fused with human fusion partner A4H12 cells. Hybridomas producing specific antibodies reactive to A549 cells were efficiently obtained by sequential cell fusion. The efficiency of acquisition of hybridom as producing specific antibodies with the in vitro immunized lymphocytes was about 10-fold higher than that with lymphocytes spontaneously immunized in bodies of lung cancer patients.",
author = "Hiroharu Kawahara and Sanetaka Shirahata and Hirofumi Tachibana and Hiroki Murakami",
year = "1992",
month = "1",
day = "1",
doi = "10.3233/HAB-1992-3102",
language = "English",
volume = "3",
pages = "8--13",
journal = "Human Antibodies",
issn = "1093-2607",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - In vitro immunization of human lymphocytes with human lung cancer cell line A549

AU - Kawahara, Hiroharu

AU - Shirahata, Sanetaka

AU - Tachibana, Hirofumi

AU - Murakami, Hiroki

PY - 1992/1/1

Y1 - 1992/1/1

N2 - We established a method of in vitro immunization of human lymphocytes against human cancer cells and efficiently obtained human-human hybridomas producing cancer-specific antibodies using the in vitro immunized lymphocytes. Human lymphocytes were cocultured with human lung cancer cell line A549 for four days in medium containing various immunoactive reagents. In vitro immunization was effectively caused by the addition of OK-432 or muramyl peptides, IL-2, and IL-6, to the coculture of A549 cells and lymphocytes. Although specific antibodies of both IgM and IgG classes were produced by this method, the ratio of IgG to IgM was ≥2. The efficiencies of in vitro immunization fluctuated about threefold in lymphocytes derived from several donors. The in vitro immunized lymphocytes were fused with human fusion partner A4H12 cells. Hybridomas producing specific antibodies reactive to A549 cells were efficiently obtained by sequential cell fusion. The efficiency of acquisition of hybridom as producing specific antibodies with the in vitro immunized lymphocytes was about 10-fold higher than that with lymphocytes spontaneously immunized in bodies of lung cancer patients.

AB - We established a method of in vitro immunization of human lymphocytes against human cancer cells and efficiently obtained human-human hybridomas producing cancer-specific antibodies using the in vitro immunized lymphocytes. Human lymphocytes were cocultured with human lung cancer cell line A549 for four days in medium containing various immunoactive reagents. In vitro immunization was effectively caused by the addition of OK-432 or muramyl peptides, IL-2, and IL-6, to the coculture of A549 cells and lymphocytes. Although specific antibodies of both IgM and IgG classes were produced by this method, the ratio of IgG to IgM was ≥2. The efficiencies of in vitro immunization fluctuated about threefold in lymphocytes derived from several donors. The in vitro immunized lymphocytes were fused with human fusion partner A4H12 cells. Hybridomas producing specific antibodies reactive to A549 cells were efficiently obtained by sequential cell fusion. The efficiency of acquisition of hybridom as producing specific antibodies with the in vitro immunized lymphocytes was about 10-fold higher than that with lymphocytes spontaneously immunized in bodies of lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0026576132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026576132&partnerID=8YFLogxK

U2 - 10.3233/HAB-1992-3102

DO - 10.3233/HAB-1992-3102

M3 - Article

C2 - 1576323

AN - SCOPUS:0026576132

VL - 3

SP - 8

EP - 13

JO - Human Antibodies

JF - Human Antibodies

SN - 1093-2607

IS - 1

ER -